Drug Profile
AVTX 611
Alternative Names: (-)-25 LY3130481; AVTX-611; CERC-611; LY-3130481Latest Information Update: 21 Nov 2022
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Avalo Therapeutics
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 08 Nov 2022 Avalo Therapeutics enters into an agreement with ES Therapeutics to sell its net economic rights to future payments of previously out-licensed assets including CERC 611
- 26 Aug 2021 Cerecor is now called Avalo Therapeutics
- 28 Oct 2020 No recent reports of development identified for preclinical development in Epilepsy in USA (PO)